Diabetes, obesity & metabolism

Effects of GLP-1 and Combined GIP/GLP-1 Drugs on Inflammation and Metabolism in Type 2 Diabetes

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual GIP/GLP-1 receptor agonists may improve cardiovascular outcomes in type 2 diabetes mellitus (T2DM).

  • The impact of GLP-1RAs on inflammatory and oxidative biomarkers is not fully understood.
  • Dual GIP/GLP-1 receptor agonists may also influence these biomarkers.
  • Further research is needed to clarify the relationship between these treatments and inflammation or oxidative stress.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Related papers

Feb '26
Inflammation marker changes with GLP-1 drugs compared to other diabetes medicines in type 2 patients
top 10% journal
systematic review
Apr '25
GLP-1 receptor drugs and their link to blood inflammation levels in type 2 diabetes
top 5% journal
cited by 46 papers
systematic review
Feb '26
GLP-1 receptor agonists and their impact on inflammation and metabolism in type 2 diabetes
top 30% journal
systematic review
Feb '26
Comparing tirzepatide and GLP-1 drugs for heart health in type 2 diabetes patients
top 2% journal
journal article
Oct '23
Tirzepatide's effects on heart rate in people with type 2 diabetes
cited by 10 papers
systematic review
Oct '25
Effectiveness of GLP-1 and combined GLP-1/GIP receptor drugs for treating fatty liver disease: a meta-analysis of clinical trials
top 30% journal
cited by 10 papers
systematic review
Oct '25
Tirzepatide treatment for adults with obesity
cited by 3 papers
systematic review
May '23
Possible effects of tirzepatide on COVID-19 infection in people with diabetes
top 20% journal
cited by 14 papers
journal article
Dec '25
Impact of GLP-1 Medications on Heart Health in Type 1 Diabetes
top 10% journal
systematic review

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
2 days ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
1 week ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
2 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
3 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
4 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
5 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
6 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
7 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
8 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief